Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Research & Development (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Research & Development for 10 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 39.77% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.0 million through Dec 2025, down 22.6% year-over-year, with the annual reading at $11.0 million for FY2025, 22.59% down from the prior year.
  • Research & Development for Q4 2025 was $2.0 million at Rein Therapeutics, up from $1.7 million in the prior quarter.
  • The five-year high for Research & Development was $5.9 million in Q1 2022, with the low at $22000.0 in Q3 2023.
  • Average Research & Development over 5 years is $3.2 million, with a median of $3.6 million recorded in 2024.
  • The sharpest move saw Research & Development crashed 99.48% in 2023, then skyrocketed 16818.18% in 2024.
  • Over 5 years, Research & Development stood at $4.6 million in 2021, then crashed by 47.34% to $2.4 million in 2022, then decreased by 17.9% to $2.0 million in 2023, then skyrocketed by 68.46% to $3.3 million in 2024, then tumbled by 39.77% to $2.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.0 million, $1.7 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.